2024 Annual Report (ENG)

Summary

SmartCella has made significant commercialization and scientific progress in 2024. In parallel, the company has focused on strengthening its infrastructure in key areas to enable scaling for continued growth and development.

In his statement, Christian Kinch, founder and Chairperson, emphasizes: “We are driven by a powerful mission: to bring cutting-edge delivery solutions and life-changing treatments to patients in need. We put patients first, offering hope by tackling some of the world’s most pressing health challenges. At the same time, we put science first, because true medical breakthroughs are born from innovation. By embracing entrepreneurship and visionary thinking, we are building SmartCella into a company that delivers both transformative healthcare solutions and long-term value for our shareholders.”

In his reflections on the year, Niklas Prager, SmartCella CEO, highlights: “With the enhanced experiences and skills of our Management Team, we have raised our operational standards. In Finance, we have built a team and processes that meet the demands of a listed company. Additionally, we have implemented an ERP system and enacted a comprehensive suite of policies, ensuring robust governance, control and structure. We also strengthened our technical, quality, and manufacturing capabilities and initiated full-scale GMP-production of heart cells in our Tullinge facility. This infrastructure will also provide scaleup and production for our other clinical assets in the future.”

The SmartCella Annual 2024 report is published in Swedish, with a translation into English. In the event of any discrepancies between the language versions, the Swedish version shall prevail.